Dr. Siddharth, G. Priyanka, Mirza Hassan


The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication. Anti-TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti-TB drug levels and other clinical factors were compared between the hepatotoxicity and non-hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity,12 showed anti-TB DIH. Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti-TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti-TB DIH in patients being treated with the currently recommended doses of first-line anti-TB treatment drugs.



Therapeutic Drug Monitoring, Hepatotoxicity, Tuberculosis

Full Text:



Lee J, Boyer JL. Molecular alterations in hepatocyte transport.Semin

Liver Dis 2000;20:373–384.

Hilsden RJ, Shaffer E. Liver structure and function. In: Thomson A, Shaffer E, editors. First principles of gastroenterology: the basis of disease and an approach to management, 4th ed. Edmonton, AB,

Canada: Astra; 2000. pp. 462–564.

Benichou C. Criteria for drug-induced liver disorder: report of an inter-national consensus meeting.J Hepatol 1990;11:272–276.

Chitturi S, Farrell G. Drug-induced liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff’s diseases of the liver, 9th ed.Philadelphia: Lippincott, Williams & Wilkins; 2002. pp. 1059–1128.

Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver.

Semin Liver Dis 2002;22:145–155.

Ostapowicz GM, Fontana R, Schiødt F, Larson A, Davern T, Steven Han H, McCashland T, Shakil A, Hay J, Hynan L,

et al.Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.Ann Intern Med 2002;137:947–954

Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuber-culosis chemotherapy under general programme conditions in Singa-pore. Int J Tuberc Lung Dis 2002;6:699–705.

Fernandez-Villar A, Sopena B, Vazquez R, Ulloa F, Fluiters E, Mosteiro M, Martinez-Vazquez C, Pineiro L. Isoniazid hepatotoxicity among drug users: the role of hepatitis C.

Clin Infect Dis2003;36:293–298.

Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL.A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.

J Acquir Immune Defic Syndr 2003;34:S21–S33.

Massacesi C, Santini D, Rocchi MB, La Cesa A, Marcucci F, Vincenzi B, Delprete S, Tonini G, Bonsignori M. Raltitrexed-induced hepato-toxicity: multivariate analysis of predictive factors.Anticancer Drugs 2003;14:533–541.

Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y,Mizushima Y. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate: risk factors and response to folic acid.

Scand J Rheumatol 1999;28:273–281.

Pernod J. Hepatic tolerance of ethionamide.Am Rev Respir Dis1965; 92:39–42.

Phillips S, Tashman H. Ethionamide jaundice.Am Rev Respir Dis1963;87:896–898.

British Tuberculosis Association. A comparison of the toxicity of prothi-onamide and ethionamide: a report from the research committee of the British Tuberculosis Association.


Somner AR, Brace AA. Changes in serum transaminase due to prothio-namide.Tubercle1967;48:137–143.


  • There are currently no refbacks.